Analyst Price Target is $10.20
▲ +378.87% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Caribou Biosciences in the last 3 months. The average price target is $10.20, with a high forecast of $19.00 and a low forecast of $3.00. The average price target represents a 378.87% upside from the last price of $2.13.
Current Consensus is
Buy
The current consensus among 4 investment analysts is to buy stock in Caribou Biosciences. This rating changed within the last month from a Moderate Buy consensus rating.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Read More